Literature DB >> 17330283

Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs.

J R Curtis1, C Martin, K G Saag, N M Patkar, J Kramer, D Shatin, J Allison, M M Braun.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17330283     DOI： 10.1002/art.22544

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  10 in total

1.  Validity of self-report of infections in a longitudinal cohort of patients with rheumatoid arthritis differs by source of report and infection severity.

Authors:  Julia F Simard; Matthew L Stoll; Nancy A Shadick; Elizabeth W Karlson; Daniel H Solomon
Journal:  J Clin Epidemiol       Date:  2010-04-28       Impact factor: 6.437

2.  Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.

Authors:  Carlos G Grijalva; Lang Chen; Elizabeth Delzell; John W Baddley; Timothy Beukelman; Kevin L Winthrop; Marie R Griffin; Lisa J Herrinton; Liyan Liu; Rita Ouellet-Hellstrom; Nivedita M Patkar; Daniel H Solomon; James D Lewis; Fenglong Xie; Kenneth G Saag; Jeffrey R Curtis
Journal:  JAMA       Date:  2011-11-06       Impact factor: 56.272

3.  Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.

Authors:  Huifeng Yun; Fenglong Xie; Elizabeth Delzell; Lang Chen; Emily B Levitan; James D Lewis; Kenneth G Saag; Timothy Beukelman; Kevin Winthrop; John W Baddley; Jeffrey R Curtis
Journal:  Ann Rheum Dis       Date:  2014-03-07       Impact factor: 19.103

4.  Understanding the burden of tuberculosis among American Indians/Alaska Natives in the U.S.: a validation study.

Authors:  Laura Jean Podewils; Emily Alexy; Stephani Jean Driver; James E Cheek; Robert C Holman; Dana Haberling; Meghan Brett; Eugene McCray; John T Redd
Journal:  Public Health Rep       Date:  2014 Jul-Aug       Impact factor: 2.792

5.  Validity of physician-reported hospitalized infections in a US arthritis registry.

Authors:  Jeffrey R Curtis; Nivedita M Patkar; Archana Jain; Jeffrey Greenberg; Daniel H Solomon
Journal:  Rheumatology (Oxford)       Date:  2009-08-04       Impact factor: 7.580

6.  Computerized definitions showed high positive predictive values for identifying hospitalizations for congestive heart failure and selected infections in Medicaid enrollees with rheumatoid arthritis.

Authors:  Carlos G Grijalva; Cecilia P Chung; C Michael Stein; Patricia S Gideon; Shannon M Dyer; Edward F Mitchel; Marie R Griffin
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-09       Impact factor: 2.890

7.  Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.

Authors:  J R Curtis; S Yang; N M Patkar; L Chen; J A Singh; G W Cannon; T R Mikuls; E Delzell; K G Saag; M M Safford; S DuVall; K Alexander; P Napalkov; Kevin L Winthrop; M J Burton; A Kamauu; J W Baddley
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-07       Impact factor: 4.794

8.  Geographic distribution of endemic fungal infections among older persons, United States.

Authors:  John W Baddley; Kevin L Winthrop; Nivedita M Patkar; Elizabeth Delzell; Timothy Beukelman; Fenglong Xie; Lang Chen; Jeffrey R Curtis
Journal:  Emerg Infect Dis       Date:  2011-09       Impact factor: 6.883

Review 9.  Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature.

Authors:  Trung N Tran; Herve Caspard; Fabio Magrini
Journal:  Open Access Rheumatol       Date:  2013-03-19

10.  Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab.

Authors:  K A Foley; P F Wang; B L Barber; S R Long; J E Bagalman; V Wagner; X Song; Z Zhao
Journal:  Ann Oncol       Date:  2010-01-25       Impact factor: 32.976
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.